Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Jesse Pelletier – The Role of Povidone-iodine in COVID-19

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 6th 2020

Jesse Pelletier (Ocean Ophthalmology Group, North Miami Beach, FL, USA) discusses the role of the antiseptic povidone-iodine (PVP-I), which is now routinely employed and will play a greater role in the future of healthcare, particularly in the COVID-19 era.

Questions:

1. Tell us about infection control in your office during this pandemic and where povidone-iodine (PVP-I) fits in?
2. What is the rationale behind PVP-I utilization in the nose and mouth?
3. Can you simply dilute “stock” PVP-I and use it?
4. Are these strategies broadly applicable to other specialties across medicine?

Disclosure: Jesse Pelletier is co-founder of Veloce BioPharma and Halodine, LLC.

touchOPHTHALMOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Commissioned, edited and funded by Touch Medical Media
Published: 6 August 2020

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup